Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Etoposide in Platinum-resistant Recurrent Ovarian Cancer
NCT03298074Phase 2Unknown
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in ovarian cancer. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03298074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298074.